Concurrent 1F: From Evidence to Access: Laying the Foundation for Long-Acting Depot Buprenorphine (LADB) in LMICs
Tracks
Track 6
| Wednesday, October 15, 2025 |
| 1:45 PM - 3:15 PM |
Details
Despite its potential to expand treatment options and improve outcomes, access to long-acting depot buprenorphine (LADB) remains extremely limited in low- and middle-income countries (LMICs). Recent investment by Unitaid in hepatitis C prevention presents a critical opportunity to generate and disseminate evidence on the feasibility and impact that LADB could have in LMICs, and to lay the foundation for broader access.
Speaker
Market Access And Strategic Partnerships Lead Viviana Rivas
Market Access Lead
PATH
From Evidence to Access: Laying the Foundation for Long-Acting Depot Buprenorphine (LADB) in LMICs
1:45 PM - 3:15 PMBiography
